Trial Profile
A Phase I/IIa, Randomized, Double-blind, Placebo Controlled Study to Evaluate the Safety, and Pharmacokinetics of Single and Multiple Ascending Dose of RP3128 in HV and Effect on LAR to Allergen Challenge in Mild Asthmatics
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 03 Jan 2022
Price :
$35
*
At a glance
- Drugs RP 3128 (Primary)
- Indications Asthma
- Focus Adverse reactions; First in man; Proof of concept
- Sponsors Rhizen Pharmaceuticals
- 21 Mar 2018 Status changed from recruiting to discontinued.
- 01 Jan 2018 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.
- 01 Jan 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Jun 2018.